Luis Phillip Kuschel

Luis Phillip Kuschel

Auto-generated profile, based on publicly available information

Luis Phillip Kuschel

Department of Neurosurgery, LMU University Hospital, LMU Medizin, Marchioninistraße 15, Munich, 81377, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKonstantin Helmsauer
Konstantin Helmsauer
M(Maria Stefanova (Valieva)
Maria Stefanova (Valieva)
SASalaheddine Ali
Salaheddine Ali
RGRocío Chamorro González
Rocío Chamorro González
RSRobert Schöpflin
Robert Schöpflin
RKRichard P. Koche
Richard P. Koche
MYCN amplification drives one in six cases of neuroblastoma. The supernumerary gene copies are commonly found on highly rearranged, extrachromosomal circular DNA (ecDNA). The exact amplicon structure has not been described thus far and the functional relevance of its rearrangements is unknown. Here, we analyze the MYCN amplicon structure using short-read and Nanopore sequencing and its chromatin landscape using ChIP-seq, ATAC-seq and Hi-C. This reveals two distinct classes of amplicons which explain the regulatory requirements for MYCN overexpression. The first class always co-amplifies a proximal enhancer driven by the noradrenergic core regulatory circuit (CRC). The second class of MYCN amplicons is characterized by high structural complexity, lacks key local enhancers, and instead contains distal chromosomal fragments harboring CRC-driven enhancers. Thus, ectopic enhancer hijacking can compensate for the loss of local gene regulatory elements and explains a large component of the structural diversity observed in MYCN amplification.

9 November 2022 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
LKLuis P. Kuschel
Luis P. Kuschel
JHJürgen Hench
Jürgen Hench
SFStephan Frank
Stephan Frank
IHIvana Bratic Hench
Ivana Bratic Hench
EGElodie Girard
Elodie Girard
PEPhilipp Euskirchen
Philipp Euskirchen
Background: DNA methylation‐based classification of cancer provides a comprehensive molecular approach to diagnose tumours. In fact, DNA methylation profiling of human brain tumours already profoundly impacts clinical neuro‐oncology. However, current implementation using hybridisation microarrays is time consuming and costly. We recently reported on shallow nanopore whole‐genome sequencing for rapid and cost‐effective generation of genome‐wide 5‐methylcytosine profiles as input to supervised classification. Here, we demonstrate that this approach allows us to discriminate a wide spectrum of primary brain tumours.Results: Using public reference data of 82 distinct tumour entities, we performed nanopore genome sequencing on 382 tissue samples covering 46 brain tumour (sub)types. Using bootstrap sampling in a cohort of 55 cases, we found that a minimum set of 1000 random CpG features is sufficient for high‐confidence classification by ad hoc random forests. We implemented score recalibration as a confidence measure for interpretation in a clinical context and empirically determined a platform‐specific threshold in a randomly sampled discovery cohort (N = 185). Applying this cut‐off to an independent validation series (n = 184) yielded 148 classifiable cases (sensitivity 80.4%) and demonstrated 100% specificity. Cross‐lab validation demonstrated robustness with concordant results across four laboratories in 10/11 (90.9%) cases. In a prospective benchmarking (N = 15), the median time to results was 21.1 h.Conclusions: In conclusion, nanopore sequencing allows robust and rapid methylation‐based classification across the full spectrum of brain tumours. Platform‐specific confidence scores facilitate clinical implementation for which prospective evaluation is warranted and ongoing.

21 May 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MSMichèle Simon
Michèle Simon
LKLuis P. Kuschel
Luis P. Kuschel
KHKatja von Hoff
Katja von Hoff
DYDongsheng Yuan
Dongsheng Yuan
PDPablo Hernáiz Driever
Pablo Hernáiz Driever
PEPhilipp Euskirchen
Philipp Euskirchen
Background: Although cavitating ultrasonic aspirators are commonly used in neurosurgical procedures, the suitability of ultrasonic aspirator-derived tumor material for diagnostic procedures is still controversial. Here, we explore the feasibility of using ultrasonic aspirator-resected tumor tissue to classify otherwise discarded sample material by fast DNA methylation-based analysis using low pass nanopore whole genome sequencing. Methods: Ultrasonic aspirator-derived specimens from pediatric patients undergoing brain tumor resection were subjected to low-pass nanopore whole genome sequencing. DNA methylation-based classification using a neural network classifier and copy number variation analysis were performed. Tumor purity was estimated from copy number profiles. Results were compared to microarray (EPIC)-based routine neuropathological histomorphological and molecular evaluation. Results: 19 samples with confirmed neuropathological diagnosis were evaluated. All samples were successfully sequenced and passed quality control for further analysis. DNA and sequencing characteristics from ultrasonic aspirator-derived specimens were comparable to routinely processed tumor tissue. Classification of both methods was concordant regarding methylation class in 17/19 (89%) cases. Application of a platform-specific threshold for nanopore-based classification ensured a specificity of 100%, whereas sensitivity was 79%. Copy number variation profiles were generated for all cases and matched EPIC results in 18/19 (95%) samples, even allowing the identification of diagnostically or therapeutically relevant genomic alterations. Conclusion: Methylation-based classification of pediatric CNS tumors based on ultrasonic aspirator-reduced and otherwise discarded tissue is feasible using time- and cost-efficient nanopore sequencing.

8 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
LKLuis P. Kuschel
Luis P. Kuschel
JHJürgen Hench
Jürgen Hench
SFStephan Frank
Stephan Frank
IHIvana Bratic Hench
Ivana Bratic Hench
EGElodie Girard
Elodie Girard
PEPhilipp Euskirchen
Philipp Euskirchen
DNA methylation-based classification of cancer provides a comprehensive molecular approach to diagnose tumors. In fact, DNA methylation profiling of human brain tumors already profoundly impacts clinical neuro-oncology. However, current implementations using hybridization microarrays are time-consuming and costly. We recently reported on shallow nanopore whole-genome sequencing for rapid and cost-effective generation of genome-wide 5-methylcytosine profiles as input to supervised classification using random forests complemented by a medium-resolution copy number profile derived from the same raw data. Here, we demonstrate that this approach allows to discriminate a wide spectrum of primary brain tumors using public reference data of 82 distinct tumor entities. We developed a pseudo-probability score as a confidence score for interpretation in a clinical context. Using bootstrap sampling in a discovery cohort of N = 56 cases, we find that a minimum set of 1,000 random CpG features is sufficient for high-confidence classification by ad hoc random forests for most cases and demonstrate robustness across laboratories with matching results in 13/13 cases. When applying the confidence score threshold to an independent validation series (N = 111), the method demonstrated 100% specificity for the remaining 93 cases. In a prospective benchmarking (N = 15), median time to results was 21.1 hours. In conclusion, nanopore sequencing allows robust and rapid methylation-based classification across the full spectrum of brain tumors. The integrated confidence score facilitates possible clinical implementation, while requiring further prospective evaluation.

17 March 2026 in Blood
Verified
Journal Article
Closed access
LKLeon D. Kaulen
Leon D. Kaulen
LNLakshmi Nayak
Lakshmi Nayak
PKPhilipp Karschnia
Philipp Karschnia
IKImke Kraai
Imke Kraai
DGDaniela Raffaela Galluzzo
Daniela Raffaela Galluzzo
WWWolfgang Wick
Wolfgang Wick
Immunodeficiency-associated primary CNS lymphoma (ID-PCNSL) represents a clinicopathologically distinct PCNSL subtype, for which large studies and prognostic models are lacking. To address this gap, the International PCNSL Collaborative Group conducted an international retrospective multi-center study, integrating clinical, radiological, and pathological data from 308 ID-PCNSL, diagnosed at 23 participating sites in 7 countries. Pre-existing immunodeficiency included administration of immunosuppressants for transplantation (41.2%) or autoimmunity (36.7%), and HIV infection (21.7%). All tumors were diffuse large B-cell lymphomas, with Epstein-Barr virus (EBV) detected in 79.2%. Immune reconstitution together with rituximab-methotrexate-(RM)-based chemotherapy was associated with highest response rates and prolonged progression-free survival, irrespective of immunodeficiency subtype and EBV status. Survival outcomes were highly variable with a 54-month median overall survival. Multivariable Cox regression identified age (per year increment HR: 1.05 (95%-CI:1.02-1.07); p < 0.001), Karnofsky Performance status (KPS) < 70 (HR: 3.10 (95%-CI:1.67-5.87); p < 0.001), EBV positivity (HR: 3.26 (95%-CI:1.47-7.33); p = 0.004) as prognostic factors for OS. A prognostic score was developed based on the sum of these adverse variables (age > 60 years, KPS < 70, EBV positivity). Stratification by this score yielded median survival times of 135, 29, and 3 months in patients with up to one, two and three unfavorable markers (p < 0.0001). It allowed improved prognostic stratification of ID-PCNSL as compared to the well-established MSKCC and IELSG models developed for immunocompetent PCNSL. Collectively, this large international cohort defines clinicobiologic features of ID-PCNSL and introduces an easily applicable prognostic system with potential to guide future management.

15 May 2026 in Brain and Spine
Verified
Journal Article
Open access
Biyan Nathanael HarapanBiyan Nathanael Harapan
Biyan Nathanael Harapan
AWAntonia Clarissa Wehn
Antonia Clarissa Wehn
LKLuis Kuschel
Luis Kuschel
JHJanine Herrmann
Janine Herrmann
BGBéatrice Grabein
Béatrice Grabein
MSMichael Schmutzer
Michael Schmutzer
Postoperative surgical site infections (brain abscesses and empyemas) are serious complications after neurosurgical procedures and differ from primary abscesses regarding risk factors, pathogen spectrum, and clinical course. What are the clinical characteristics, laboratory and microbiological profiles, and longitudinal DWI/ADC imaging changes of postoperative surgical site infections, and which factors are associated with patient outcome? This retrospective single-center study included patients treated for postoperative surgical site infections between 2014 and 2024. Demographics, surgical methods, comorbidities, neurological scales (GCS, KPS, GOS, mRS), laboratory markers (CRP, leukocytes, IL-6), antibiotic therapy, and microbiology were analyzed. Serial MRI with DWI and ADC quantification was evaluated preoperatively and at three postoperative time points (within 7 days, 4–12 weeks, and last follow-up). 113 patients (55 males, 58 females) had a mean age of 56.8 ± 15.1 years and underwent 361 surgeries (3.2/patient); bone flap removal was necessary in 73.5%. The presence of a diffusion restriction decreased from 60.4% preoperatively to 16.1% at final follow-up, accompanied by a significant postoperative ADC increase. Infections most frequently followed surgery for glioma (37.2%) and meningioma (22.1%). Staphylococci and Gram-negative bacteria predominated; polymicrobial infections were frequent. Mean total antibiotic duration was 48.0 ± 25.9 days (epidural infections) and 44.1 ± 19.3 days (subdural infections) (p=0.4). Postoperative surgical site infections exhibit distinct microbiology and risk patterns. Combined surgical revision and targeted prolonged antibiotics are essential. Longitudinal DWI and ADC quantification serve as objective imaging biomarkers for monitoring abscess activity and treatment response.